Evaluation of the additive effect of interferon α 2b with monthly intravitreal injection of bevacizumab in refractory diabetic macular edema

Table 3 Comparing groups based on CMT and CDVA among groups at each time point in eyes with CMT > 400 microns

Variables		Groups			Total P-value	P-value (Group 1 vs. 2)	P-value (Group 1 vs. 3)	P-value (Group 2 vs. 3)
Variables		IVB + IFN Drop (Group 1)	IVB + IFN Injection (Group 2)	IVB (Group 3)	Total P-value	P-value (Group 1 vs. 2)	P-value (Group 1 vs. 3)	P-value (Group 2 vs. 3)
CMT (microns)	Baseline	597 ± 199	610 ± 237	610 ± 156	0.973^†	0.998	0.995	0.999
	1st month	522 ± 224	444 ± 123	544 ± 96	0.049*	0.460	0.970	0.042
	Change	− 74 ± 167	− 166 ± 210	− 65 ± 115
	P-within^§	0.246	0.018	0.134
	2nd month	479 ± 171	511 ± 178	539 ± 94	0.390*	0.933	0.438	0.938
	Change	− 118 ± 158	− 99 ± 111	− 71 ± 97
	P-within^§	0.004	0.140	0.021
	3rd month	535 ± 223	465 ± 133	560 ± 100	0.090*	0.566	0.958	0.083
	Change	− 61 ± 182	− 145 ± 231	− 50 ± 96
	P-within^§	0.722	0.035	0.222
CDVA (LogMAR)	Baseline CDVA	0.89 ± 052	0.75 ± 0.46	0.89 ± 0.49	0.668^†	0.814	0.999	0.824
	1st month	0.81 ± 0.51	0.69 ± 0.28	0.77 ± 0.33	0.653*	0.785	0.989	0.876
	Change	− 0.08 ± 0.38	− 0.06 ± 0.40	− 0.12 ± 0.28
	P-within^‡	0.999	0.999	0.486
	2nd month	0.68 ± 0.40	0.82 ± 0.40	0.87 ± 0.41	0.328*	0.649	0.410	0.987
	Change	− 0.21 ± 0.38	0.07 ± 0.21	− 0.02 ± 0.19
	P-within^‡	0.080	0.999	0.999
	3rd month	0.71 ± 0.48	0.70 ± 0.36	0.85 ± 0.38	0.482*	0.999	0.700	0.619
	Change	− 0.18 ± 0.42	− 0.05 ± 0.26	− 0.04 ± 0.12
	P-within^‡	0.324	0.999	0.999

Bold values denote statistical significance at the p value < 0.05 level
^†Based on ANOVA, between comparison adjusted by Bonferroni method
^§Based on linear mixed model, comparison with baseline value, adjusted for the multiple comparisons by Bonferroni method
*Based on ANCOVA, adjusted for the baseline value, between-group comparison adjusted by Bonferroni method
^‡Based on Wilcoxon signed rank test, compared with baseline value

ISSN: 2056-9920